![John Hyttel](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Oorsprong van het eerstegraads netwerk van John Hyttel
Entiteit | Type entiteit | Industrie | |
---|---|---|---|
Public Company | Pharmaceuticals: Major | 34 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met John Hyttel via zijn persoonlijke netwerk
Onderneming | Sector | Gelieerde personen | Hoofdpost |
---|---|---|---|
TDC A/S | Major Telecommunications | Corporate Officer/Principal Corporate Officer/Principal | |
NOVO NORDISK A/S | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
H. LUNDBECK A/S | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
NTG NORDIC TRANSPORT GROUP A/S | Trucking | Corporate Officer/Principal Investor Relations Contact | |
University of Oxford | College/University | Undergraduate Degree Undergraduate Degree | |
ATON | Pharmaceuticals: Major | Director/Board Member Chairman Chairman | |
VALERIO THERAPEUTICS | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
Copenhagen Business School | College/University | Undergraduate Degree Graduate Degree Graduate Degree | |
University of Aarhus | College/University | Corporate Officer/Principal Graduate Degree Masters Business Admin | |
Zymenex A/S
![]() Zymenex A/S BiotechnologyHealth Technology Zymenex A/S researches and develops therapeutics for life threatening diseases. The firm commercializes novel enzyme replacement therapies for the treatment of life-threatening, rare genetic diseases. The company was founded by Jens Fogh and Pär Gellerfors in 1998 and is headquartered in Hillerod, Denmark. | Biotechnology | Chairman Chairman | |
Technical University of Denmark | College/University | Graduate Degree Graduate Degree | |
Roche Innovation Center Copenhagen A/S
![]() Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | Pharmaceuticals: Major | Chairman Director/Board Member Chairman | |
CELLECTIS S.A. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
University of Lund | College/University | Graduate Degree Doctorate Degree Graduate Degree Undergraduate Degree | |
University of Copenhagen | College/University | Corporate Officer/Principal Doctorate Degree Doctorate Degree Undergraduate Degree Graduate Degree Graduate Degree Doctorate Degree Doctorate Degree | |
International Institute for Management Development | College/University | Masters Business Admin Undergraduate Degree Masters Business Admin | |
Danmarks Farmaceutiske Universitet | College/University | Graduate Degree Graduate Degree | |
F2G Ltd.
![]() F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Chairman | |
The European Molecular Biology Laboratory | College/University | Corporate Officer/Principal | |
Warren Pharmaceuticals, Inc.
![]() Warren Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Warren Pharmaceuticals, Inc. develops tissue-protective technologies. The company was founded by Anthony Cerami and Michael Brines on May 17, 2001 and is headquartered in Tarrytown, NY. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
OxThera AB
![]() OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Generic | Director/Board Member Director/Board Member Director/Board Member | |
Critical Care Diagnostics, Inc.
![]() Critical Care Diagnostics, Inc. Medical SpecialtiesHealth Technology Critical Care Diagnostics, Inc. develops diagnostic tools. The firm offers Presage, a laboratory assay employing ST2 for the diagnosis and prognosis of cardiovascular disease. It also offers Aspect-PLUS ST2 test, a cardiac biomarker testing product that aids clinicians in assessing risk, making treatment decisions, evaluating therapy effectiveness, and monitoring patient care. The company was founded by Sven M. Jacobson and David M. Geliebter in 2004 and is headquartered in San Diego, CA. | Medical Specialties | Chief Tech/Sci/R&D Officer | |
Remedy Pharmaceuticals, Inc.
![]() Remedy Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Remedy Pharmaceuticals, Inc. develops and commercializes pharmaceutical ingridients. It focuses on small molecule drugs for acute central nervous system disorders. The company was founded by David M. Geliebter and Sven M. Jacobson in 2004 and is headquartered in New York, NY. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
ADOCIA | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
AM-Pharma BV
![]() AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Biotechnology | Director/Board Member Director/Board Member | |
Weill Cornell Medical College | College/University | Doctorate Degree | |
Vital Sensors Holding Co., Inc.
![]() Vital Sensors Holding Co., Inc. Electronic Equipment/InstrumentsElectronic Technology Vital Sensors Holding Co., Inc. Develops chip based pressure sensors. It offers continuous or on demand data capture and read out capabilities that will support clinicians and patients in the management of cardiovascular and other disease state. The company was founded in 2002 by Volker Bödecker and Max Georg Ostermeier and is headquartered in Richmond, VA. | Electronic Equipment/Instruments | Chief Operating Officer | |
ORPHAZYME A/S | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
Kymab Ltd.
![]() Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Chief Executive Officer Founder | |
AVT Business School A/S | College/University | Chairman Masters Business Admin | |
Rigshospitalet
![]() Rigshospitalet Hospital/Nursing ManagementHealth Services Rigshospitalet is a highly specialized hospital in Denmark that ensures all patients in Denmark have a treatment offer, no matter how rare or complicated their illness is. The hospital is located on Blegdamsvej and in Glostrup. Rigshospitalet prioritizes research and achieves and disseminates results through extensive national and international cooperation. The hospital has subsidiaries in Denmark. | Hospital/Nursing Management | Corporate Officer/Principal | |
American Chamber of Commerce In Denmark
![]() American Chamber of Commerce In Denmark Miscellaneous Commercial ServicesCommercial Services The American Chamber of Commerce in Denmark is an organization that provides news, events, membership forums, and resources related to business in Denmark. The American Chamber of Commerce in Denmark is based in Copenhagen, Denmark. The organization focuses on promoting transatlantic data flows and foreign direct investments. Recently, the Danish government announced that it will invest 143 billion kroner in defense over the next decade. The organization also holds more than 50 events a year, including seminars and workshops on topics such as workforce planning and Danish taxation for expats. | Miscellaneous Commercial Services | Director/Board Member | |
Key Neurosciences SAS
![]() Key Neurosciences SAS Miscellaneous Commercial ServicesCommercial Services Key Neurosciences SAS provides research and development services. Its services include product and technology development, fund raising, business and commercial development, and project management. The company was founded in December 2010 and is headquartered in Paris, France. | Miscellaneous Commercial Services | Director/Board Member Chairman | |
VALNEVA | Biotechnology | Corporate Officer/Principal Director/Board Member | |
Dansk Selskab for Flowcytometri | Director/Board Member | ||
The Danish Business Authority | National Agency | Chief Executive Officer | |
ALTAMIRA THERAPEUTICS LTD. | Biotechnology | Director/Board Member Director/Board Member | |
Auris Medical AG
![]() Auris Medical AG Medical SpecialtiesHealth Technology Auris Medical AG manufactures electronic devices for ear disorders. It develops novel pharmaceutical therapies to protect hearing and to silence tinnitus. The company was founded by Thomas Meyer in April 2003 and is headquartered in Basel, Switzerland. | Medical Specialties | Director/Board Member Director/Board Member |
Statistieken
Internationaal
Denemarken | 21 |
Frankrijk | 10 |
Verenigde Staten | 8 |
Zwitserland | 5 |
Verenigd Koninkrijk | 4 |
Sectoraal
Health Technology | 27 |
Consumer Services | 12 |
Commercial Services | 6 |
Finance | 3 |
Communications | 2 |
Operationeel
Director/Board Member | 241 |
Corporate Officer/Principal | 72 |
Chairman | 64 |
Independent Dir/Board Member | 49 |
Chief Executive Officer | 32 |
Sterkste connecties
Insiders | |
---|---|
Peter James Arthur Benson | 58 |
Alain Munoz | 38 |
Christian Herskind Jørgensen | 35 |
Rémi Droller | 29 |
Jørgen Lindegaard | 22 |
David Solomon | 22 |
Jutta af Rosenborg | 21 |
Michael Owen | 20 |
Leif Helth Jensen | 20 |
Jean-Christophe Renondin | 15 |
Florian Reinaud | 15 |
Bo Lennart Bruce | 15 |
Mats Blom | 15 |
Anders Fink Vadsholt | 13 |
Jesper Zeuthen | 13 |
- Beurs
- Insiders
- John Hyttel
- Bedrijfsconnecties